Posted by Michael Wonder on 05 Dec 2016
TGA approves AbbVie's Technivie
5 December 2016 - The TGA has approved another AbbVie combination product for use by patients with chronic hepatitis C virus infection.
The TGA approved Technivie (paritaprevir with ritonavir and ombitasvir) on 30 November 2016 for use in combination with ribavirin for the treatment of adult patients with genotype 4 chronic hepatitis C virus infection.
